CoChat

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?

Inzucchi, Silvio E., Fitchett, David, Jurišić‐Eržen, Dubravka, Woo, Vincent, Hantel, Stefan, Janista, Christina, Kaspers, Stefan, George, Jyothis T., Zinman, Bernard, on behalf of the EMPA‐REG OUTCOME® Investigators · 2020 · Diabetes, Obesity and Metabolism
Cited by 82

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Aims: In the EMPA‐REG OUTCOME® trial, the sodium‐glucose cotransporter 2 inhibitor empagliflozin when given in addition to standard care improved cardiovascular (CV) and renal outcomes, and reduced mortality. Trial participants were on a variety of glucose‐lowering therapies at baseline, some of which could potentially affect CV risk. This analysis investigated whether the use of background diabetes therapy affected the risk of CV death, hospitalizations for heart failure, and progression of chronic kidney disease, among patients treated with empagliflozin. Materials and methods: Patients meeting inclusion and exclusion criteria were randomized to placebo, empagliflozin 10 mg or empagliflozin 25 mg; glucose‐lowering therapy was to remain unchanged for 12 weeks and then adjusted to achieve glycaemic control according to local guidelines. Differences in risk of cardio‐renal outcomes between empagliflozin and placebo by baseline use of metformin, sulphonylurea (SU) and insulin were assessed using a Cox proportional hazards model. Results: Of 7020 eligible patients, 74% were receiving metformin, 43% SU and 48% insulin at baseline (each alone or in combination); the most common regimens were metformin plus SU (20%) and metformin plus insulin (20%). Empagliflozin reduced the risk of CV death irrespective of the use of: metformin [with: hazard ratio (HR) 0.71 (95% confidence interval, CI, 0.54–0.94); without: 0.46 (0.32–0.68); P interaction = 0.07]; SU [with: HR 0.64 (0.44–0.92); without: 0.61 (0.46–0.81); P interaction = 0.85]; or insulin [with: HR 0.63 (0.46–0.85); without: 0.61 (0.44–0.85); P interaction = 0.92]. Reductions in three‐point major adverse CV events, hospitalizations for heart failure, and all‐cause mortality were consistent across subgroups of baseline therapies. Empagliflozin reduced the risks of incident or worsening nephropathy versus placebo irrespective of the use of SU or insulin at baseline ( P interaction > 0.05), but there was a greater reduction in this risk for patients not using metformin [HR 0.47 (95% CI 0.37–0.59)] versus those using metformin [HR 0.68 (95% CI 0.58–0.79)] at baseline ( P interaction = 0.01). Conclusions: The addition of empagliflozin to antihyperglycaemic regimens of patients with type 2 diabetes and CV disease consistently reduced their risks of adverse CV outcomes and mortality irrespective of baseline use of metformin, SU or insulin. For chronic kidney disease progression, there may be a larger benefit from empagliflozin in those patients who are not using metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13938

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 82

Metadata

Authors
Inzucchi, S. E., Fitchett, D., Jurišić‐Eržen, D., Woo, V., Hantel, S., Janista, C., Kaspers, S., George, J. T., Zinman, B., & on behalf of the EMPA‐REG OUTCOME® Investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2020-01-03
Volume
22
Issue
4
Pages
631-639
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2993540759
Cited by
82
References
14
FWCI
10.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy? https://app.cochat.ai/papers/10.1111/dom.13938
The paper
Inzucchi, S. E., Fitchett, D., Jurišić‐Eržen, D., Woo, V., Hantel, S., Janista, C., Kaspers, S., George, J. T., Zinman, B., & on behalf of the EMPA‐REG OUTCOME® Investigators. (2020). Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy? Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13938

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.